Contact Investor Relations

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Contact Investor Relations

Primary IR Contact

Joshua Drumm, Ph.D.
Phone: 212-375-2664
E-mail: jdrumm@tiberend.com